Antidepressant-induced jitteriness/anxiety syndrome: Systematic review

British Journal of Psychiatry

Volumn 194, Issue 6, 2009, Pages 483-490

  Sinclair, Lindsey I ^a   Christmas, David M ^a   Hood, Sean D ^b   Potokar, John P ^a   Robertson, Andrea ^c   Isaac, Andrew ^d   Srivastava, Shrikant ^a   Nutt, David J ^a   Davies, Simon J C ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c NHS LOTHIAN   (United Kingdom)

^d South Warwickshire Foundation Trust   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; AMFEBUTAMONE; AMOXAPINE; BENZODIAZEPINE; BUSPIRONE; CLOMIPRAMINE; DESIPRAMINE; DIAZEPAM; DOSULEPIN; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; MIANSERIN; MILNACIPRAN; MIRTAZAPINE; NEFAZODONE; PAROXETINE; PERPHENAZINE; PHENOTHIAZINE; PLACEBO; PROPRANOLOL DERIVATIVE; REBOXETINE; SERTRALINE; VENLAFAXINE;

AGITATION; AKATHISIA; ANXIETY; ANXIETY DISORDER; CLINICAL TRIAL; DEPRESSION; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG WITHDRAWAL; GENETIC PREDISPOSITION; GENETIC VARIABILITY; HUMAN; HYPERACTIVITY; HYPOMANIA; INCIDENCE; IRRITABILITY; LOW DRUG DOSE; NERVOUSNESS; OBSESSIVE COMPULSIVE DISORDER; PANIC; PREDICTOR VARIABLE; REVIEW; SIDE EFFECT; SUICIDE; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT RESPONSE; TREATMENT WITHDRAWAL;

AKATHISIA, DRUG-INDUCED; ANTIDEPRESSIVE AGENTS; ANXIETY; ANXIETY DISORDERS; DOSE-RESPONSE RELATIONSHIP, DRUG; GENETIC PREDISPOSITION TO DISEASE; HUMANS; RISK FACTORS; SEROTONIN UPTAKE INHIBITORS; SUICIDE; SYNDROME; TIME FACTORS; TREATMENT REFUSAL;

EID: 67649216251     PISSN: 00071250     EISSN: 14721465     Source Type: Journal    
DOI: 10.1192/bjp.bp.107.048371     Document Type: Review

References (58)

1. Sheehan DV, Harnett-Sheehan K. The role of SSRIs in panic disorder. J Clin Psychiatry 1996; 57 (suppl 10): 51-58 (Pubitemid 26384725)
2. Toni C, Perugi G, Frare F, Mata B, Vitale B, Mengali F, et al. A prospective naturalistic study of 326 panic-agoraphobic patients treated with antidepressants. Pharmacopsychiatry 2000; 33: 121-131 (Pubitemid 30644553)
3. Westenberg HG. Developments in the drug treatment of panic disorder: what is the place of the selective serotonin reuptake inhibitors? J Affect Disord 1996; 40: 85-93.
4. National Institute for Health and Clinical Excellence. Anxiety: Management of Anxiety (Panic Disorder, With or Without Agoraphobia, and Generalised Anxiety Disorder) in Adults in Primary, Secondary and Community Care. NICE, 2004.
5. Baldwin D, Anderson I, Nutt D, Bandelow B, Bond A, Davidson JR, et al. Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psyhcopharmacology. J Psychpharmacol 2005; 19: 567-596 (Pubitemid 41578819)
6. Hood SD, Argyropoulos SV, Nutt DJ. New directions in the treatment of anxiety disorders. Expert Opinion Ther Patents 2003; 13: 401-423 (Pubitemid 36511990)
7. Phillips B, Ball C, Sackett D, Badenoch D, Straus S, Haynes B, et al. Oxford Centre for Evidence-based Medicine Levels of Evidence. CEBM, 2001 (http://www.cebm.net/index.aspx?o=1025).
8. Food and Drug Administration. Worsening depression and suicidality in patients being treated with antidepressant. FDA Public Health Advisory, 2004.
9. Culpepper L, Davidson JR, Dietrich AJ, Goodman WK, Kroenke K, Schwenk TL. Suicidality as a possible side effect of antidepressant treatment. Prim care companion. J Clin Psychiatry 2004; 6: 79-86.
10. Amsterdam JD, Hornig-Rohan M, Maislin G. Efficacy of alprazolam in reducing fluoxetine-induced jitteriness in patients with major depression. J Clin Psychiatry 1994; 55: 394-400. (Pubitemid 24337996)
11. Ramos RT, Gentil V, Gorenstein C. Clomipramine and initial worsening in panic disorder: beyond the 'jitteriness syndrome'. J Psychpharmacol 1993; 7: 265-269
12. Yeragani VK, Pohl R, Balon R, Ramesh C, Weinberg P. Imipramine-induced jitteriness and decreased serum iron levels. Neuropsychobiology 1992; 25: 8-10.
13. Beasley Jr CM, Sayler ME, Bosomworth JC, Wernicke JF. High-dose fluoxetine: efficacy and activating-sedating effects in agitated and retarded depression. J Clin Psychopharmacol 1991; 11: 166-174
14. Beasley Jr CM, Sayler ME, Weiss AM, Potvin JH. Fluoxetine: activating and sedating effects at multiple fixed doses. J Clin Psychopharmacol 1992; 12: 328-333
15. Harada T. A survey of activation syndrome induced by antidepressants. Int Clin Psychopharmacol 2006; 21: A9.
16. Giesecke ME. Overcoming hypersensitivity to fluoxetine in a patient with panic disorder. Am J Psychiatry 1990; 147: 532-533 (Pubitemid 20107127)
17. Gorman JM, Liebowitz MR, Fyer AJ, Goetz D, Campeas RB, Fyer MR, et al. An open trial of fluoxetine in the treatment of panic attacks. J Clin Psychopharmacol 1987; 7: 329-332 (Pubitemid 18042934)
18. Louie AK, Lewis TB, Lannon RA. Use of low-dose fluoxetine in major depression and panic disorder. J Clin Psychiatry 1993; 54: 435-438 (Pubitemid 24020599)
19. Perlis RH, Beasley Jr CM, Wines JD, Tamura RN, Cusin C, Strong RE, et al. Treatment-associated suicidal ideation and adverse effects in an open, multicenter trial of fluoxetine for major depressive episodes. Psychother Psychosom 2007; 76: 40-46 (Pubitemid 46005718)
20. Schneier FR, Liebowitz MR, Davies SO, Fairbanks J, Hollander E, Campeas R, et al. Fluoxetine in panic disorder. J Clin Psychopharmacol 1990; 10: 119-121 (Pubitemid 20137608)
21. Aronson TA. A naturalistic study of imipramine in panic disorder and agoraphobia. Am J Psychiatry 1987; 144: 1014-1019 (Pubitemid 17143559)
22. Pohl R, Yeragani VK, Balon R, Lycaki H. The jitteriness syndrome in panic disorder patients treated with antidepressants. J Clin Psychiatry 1988; 49: 100-104 (Pubitemid 18091342)
23. Zitrin CM, Klein DF, Woerner MG. Behavior therapy, supportive psychotherapy, imipramine, and phobias. Arch Gen Psychiatry 1978; 35: 307-316 (Pubitemid 8322954)
24. Jackson CW, Lydiard RB. Two cases of activation/jitteriness associated with TCAs. J Clin Psychopharmacol 1990; 10: 439-440
25. Noyes JR R, Garvey MJ, Cook BL, Samuelson L. Problems with tricyclic antidepressant use in patients with panic disorder or agoraphobia: results of a naturalistic follow-up study. J Clin Psychiatry 1989; 50: 163-169 (Pubitemid 19147273)
26. Pohl R, Yeragani VK, Ortiz A, Rainey Jr JM, Gershon S. Response of tricyclic-induced jitteriness to a phenothiazine in two patients. J Clin Psychiatry 1986; 47: 427. (Pubitemid 16045149)
27. Lotufo-Neto F, Bernik M, Ramos RT, Andrade L, Gorenstein C, Cordas T, et al. A dose-finding and discontinuation study of clomipramine in panic disorder. J Psychopharmacol 2001; 15: 13-17 (Pubitemid 32242098)
28. Ackerman DL, Greenland S, Bystritsky A. Side effects as predictors of drug response in obsessive-compulsive disorder. J Clin Psychopharmacol 1999; 19: 459-465 (Pubitemid 29451511)
29. Guile JM. Sertraline-induced behavioral activation during the treatment of an adolescent with major depression. J Child Adolesc Psychopharmacol 1996; 6: 281-285 (Pubitemid 27079646)
30. Oehrberg S, Christiansen PE, Behnke K, Borup AL, Severin B, Soegaard J, et al. Paroxetine in the treatment of panic disorder. A randomised, double-blind, placebo-controlled study. Br J Psychiatry 1995; 167: 374-379 (Pubitemid 26197752)
31. Vorstman J, Lahuis B, Buitelaar JK. SSRIs associated with behavioral activation and suicidal ideation. J Am Acad Child Adolesc Psychiatry 2001; 40: 1364-1365 (Pubitemid 34250953)
32. Liegghio NE, Yeragani VK, Moore NC. Buspirone-induced jitteriness in three patients with panic disorder and one patient with generalized anxiety disorder. J Clin Psychiatry 1988; 49: 165-166 (Pubitemid 18128731)
33. Pohl R, Balon R, Yeragani VK, Gershon S. Serotonergic anxiolytics in the treatment of panic disorder: a controlled study with buspirone. Psychopathology 1989; 22 (suppl 1): 60-67 (Pubitemid 19104670)
34. Tollefson GD, Sayler ME. Course of psychomotor agitation during pharmacotherapy of depression: analysis from double-blind controlled trials with fluoxetine. Depress Anxiety 1996; 4: 294-311. (Pubitemid 27237363)
35. Stahl SM, Mendels J, Schwartz GE. Effects of reboxetine on anxiety, agitation, and insomnia: results of a pooled evaluation of randomized clinical trials. J Clin Psychopharmacol 2002; 22: 388-392 (Pubitemid 34810328)
36. Pohl RB, Wolkow RM, Clary CM. Sertraline in the treatment of panic disorder: a double-blind multicenter trial. Am J Psychiatry 1998; 155: 1189-1195 (Pubitemid 28402511)
37. Hu XH, Bull SA, Hunkeler EM, Ming E, Lee JY, Fireman B, et al. Incidence and duration of side effects and those rated as bothersome with selective serotonin reuptake inhibitor treatment for depression: patient report versus physician estimate. J Clin Psychiatry 2004; 65: 959-965
38. Zajecka J, Amsterdam JD, Quitkin FM, Reimherr FW, Rosenbaum JF, Tamura RN, et al. Changes in adverse events reported by patients during 6 months of fluoxetine therapy. J Clin Psychiatry 1999; 60: 389-394 (Pubitemid 29289727)
39. Edwards JG, Anderson I. Systematic review and guide to selection of selective serotonin reuptake inhibitors. Drugs 1999; 57: 507-533 (Pubitemid 29196919)
40. Lipinski Jr JF, Mallya G, Zimmerman P, Pope Jr HG. Fluoxetine-induced akathisia: clinical and theoretical implications. J Clin Psychiatry 1989; 50: 339-342 (Pubitemid 19239056)
41. Akagi H, Kumar T. Akathisia: overlooked at a cost. BMJ 2002; 324: 1506-1507
42. Tollefson G, Rampey A, Beasley Jr CM, Enas G, Potvin JH. Absence of a relationship between adverse events and suicidality during pharmacotherapy for depression. J Clin Psychopharmacol 1994; 14: 163-169 (Pubitemid 24182182)
43. Hammad T. Results of the analysis of suicidality in paediatric trials of newer antidepressants. Joint meeting of the CDER psychopharmacologic drugs advisory committee and the FDA paediatric advisory committee. Department of Health and Human Services, Food and Drug Administration Centre for Drug Evaluation and Research, 2004 (http://www.fda.gov/ohrms/dockets/ac/04/ transcripts/2004-4065T1.pdf and http://www.fda.gov/ohrms/dockets/ac/04/slides/ 2004-4065S1.htm).
44. Vorstman J, Lahuis B, Buitelaar J. SSRIs Associated with behavioural activation and suicidal ideation. J Am Acad Child Adolesc Psychiatry 2001; 40: 1364-1365 (Pubitemid 34250953)
45. Putzhammer A, Schoeler A, Rohrmeier T, Sand P, Hajak G, Eichhammer P. Evidence of a role for the 5-HTTLPR genotype in the modulation of motor response to antidepressant treatment. Psychopharmacol 2005; 178: 303-308 (Pubitemid 40379225)
46. Perlis RH, Mischoulon D, Smoller JW, Wan YJ, Lamon-Fava S, Lin KM, et al. Serotonin transporter polymorphisms and adverse effects with fluoxetine treatment. Biol Psychiatry 2003; 54: 879-883 (Pubitemid 37311349)
47. Murphy Jr GM, Kremer C, Rodrigues HE, Schatzberg AF. Pharmacogenetics of antidepressant medication intolerance. Am J Psychiatry 2003; 160: 1830-1835 (Pubitemid 41103318)
48. Balon R. Selective serotonin reuptake inhibitors and suicide: is the evidence, as with beauty, in the eye of the beholder? Psychother Psychosom 2003; 72: 293-299
49. Westenberg HG, Den Boer JA. New findings in the treatment of panic disorder. Pharmacopsychiatry 1993; 26 (suppl 1): 30-33 (Pubitemid 23193096)
50. Liebowitz MR, Klein DF. Differential diagnosis and treatment of panic attacks and phobic states. Annu Rev 1981; 32: 583-599
51. Argyropoulos SV, Sandford J, Nutt DJ. The psychobiology of anxiolytic drugs. Part 2: pharmacological treatments of anxiety. Pharmacol Ther 200; 88: 213-227
52. Scott A, Davidson A, Palmer K. Antidepressant drugs in the treatment of anxiety disorders. Advan Psychiatr Treat 2001; 7: 275-282
53. Lane RM. SSRI-induced extrapyramidal side-effects and akathisia: implications for treatment. J Psychopharmacol 1998; 12: 192-214. (Pubitemid 28312578)
54. Yeragani VK, Pohl R, Balon R. Tricyclics, akathisia, and jitteriness. J Clin Psychopharmacol 1988; 8: 295.
55. Ener RA, Meglathery SB, Van Decker WA, Gallagher RM. Serotonin syndrome and other serotonergic disorders. Pain Med 2003; 4: 63-74. (Pubitemid 37161330)
56. Sachdev P, Kruk J. Restlessness: the anatomy of a neuropsychiatric symptom. Aust N Z J Psychiatry 1996; 30: 38-53.
57. Weller IVC. Report of the CSM Expert Working Group on the Safety of Selective Serotonin Reuptake Inhibitor Antidepressants. Medicines and Healthcare Regulatory Authority, 2004.
58. Bagdy G, Graf M, Anheuer ZE, Modos EA, Kantor S. Anxiety-like effects induced by acute fluoxetine, sertraline or m-CPP treatment are reversed by pretreatment with the 5-HT2C receptor antagonist SB-242084 but not the 5-HT1A receptor antagonist WAY-100635. Int J Neuropsychopharmacol 2001; 4: 399-408. (Pubitemid 33151684)